Skip to main content
    K

    Kiniksa Pharmaceuticals Ltd (KNSA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $93.86
    +5.52 (+6.25%)

    Market Cap: $6.94B

    Last updated: Nov 06, 2026 at 4:39 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(18/34)
    Avg Surprise
    -27.96%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$1.15
    Range$1.15 - $1.15
    1 analysts
    Revenue Consensus
    $357M
    Range$354M - $359M
    6 analysts
    Period ending Mar 31, 2027
    EPS Consensus$0.46
    Range$0.36 - $0.55
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.36+26.4%
    60d ago$0.36+26.4%
    30d ago$0.36+26.4%
    7d ago$0.36+26.4%
    Current$0.46
    Revenue Consensus
    $309M
    Range$282M - $321M
    6 analysts
    Last 12 of 36 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Mar 27EST
    		-$0.46$0.36 - $0.55--2
    1
    0
    30d
    		-
    Dec 26EST
    		-$1.15$1.15 - $1.15--1--
    Sep 26
    Reported Oct 27
    		$0.56$0.32$0.27 - $0.37+75.00%Beat4
    2
    2
    30d
    		+143.5%
    Jun 26
    Reported Jul 28
    		$0.30$0.30$0.27 - $0.30+0.00%Beat4
    No revisions (30d)
    		+30.4%
    Mar 26
    Reported Apr 28
    		$0.27$0.16$0.13 - $0.20+68.75%Beat3
    0
    1
    30d
    		+145.5%
    Dec 25
    Reported Feb 24
    		$0.17N/A--57.50%Miss5
    No revisions (30d)
    		+241.7%
    Sep 25
    Reported Oct 28
    		$0.23$0.37$0.26 - $0.57-37.84%Miss5
    1
    1
    30d
    		+227.8%
    Jun 25
    Reported Jul 29
    		$0.23$0.26$0.16 - $0.37-11.54%Miss5
    0
    1
    30d
    		+483.3%
    Mar 25
    Reported Apr 29
    		$0.11N/A--60.71%Miss4
    No revisions (30d)
    		+144.0%
    Dec 24
    Reported Feb 25
    		$-0.12$0.02$-0.13 - $0.33-700.00%Miss3
    No revisions (30d)
    		-134.3%
    Sep 24
    Reported Oct 29
    		$-0.18$0.07$-0.06 - $0.18-357.14%Miss5
    1
    0
    30d
    		+10.0%
    Jun 24
    Reported Jul 23
    		$-0.06$0.01$-0.04 - $0.08-700.00%Miss4
    No revisions (30d)
    		-128.6%
    Mar 24
    Reported Apr 23
    		$-0.25$-0.08$-0.14 - $-0.05-212.50%Miss3
    No revisions (30d)
    		-38.9%
    Dec 23
    Reported Feb 28
    		$0.35$-0.14$-0.23 - $-0.04+350.00%Beat4
    No revisions (30d)
    		+483.3%

    Key Metrics

    Valuation
    P/E Ratio72.20EV/EBITDA48.98x
    Price/FCF37.22xFCF Yield2.69%
    Profitability
    Profit Margin11.60%Operating Margin19.00%
    ROE17.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio3.91xQuick Ratio3.35x
    Trading Statistics
    Beta0.08Avg Volume939.24K
    52-Week High$98.4852-Week Low$37.02

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$90.96
    SMA 20$85.23
    SMA 50$80.46
    SMA 200$61.50
    EMA 10$90.39
    EMA 20$86.88
    EMA 50$81.40
    EMA 200$64.91

    MACD

    Line: 4.16Signal: 3.40Hist: 0.76

    ADX

    ADX: 18.8+DI: 25.8-DI: 19.8

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down64.0
    PSAR$82.10

    Bollinger Bands

    Upper Band$100.57
    Lower Band$69.89
    %B Position3601%(Upper)
    Band Width0.78

    RSI (14-Day)

    Neutral
    59.8

    Momentum Oscillators

    Stoch %K79.5
    Stoch %D80.0
    Williams %R-16.6
    ROC (10d)22.3%
    Momentum17.13
    CCI (20d)70.6
    MFI (14d)59.9

    Volatility Measures

    ATR (14d)$5.06(5.4%)
    StdDev (20d)7.67
    Hist Vol101.5%(High)

    Volume Flow

    VWAP$92.25
    OBV30.9M
    AD Line18.6M
    CMF (20d)0.041

    Volume Metrics

    Avg Vol (20d)991.1K
    Vol Ratio0.6x
    VWMA (20d)$86.65

    Pivot Points

    R3$104.14
    R2$100.57
    R1$94.45
    Pivot Point$90.88
    S1$84.76
    S2$81.19
    S3$75.07

    Advanced Oscillators

    TSI22.10
    Ultimate Osc51.3
    KST155.45

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$285.97M$243.60M$214.27M$202.13M$180.85M$156.80M$137.78M$122.54M$112.21M$108.63M$79.86M$83.39M
    Cost of Revenue$133.59M$111.64M$96.37M$90.97M$83.56M$71.02M$61.66M$66.08M$49.42M$42.34M$31.38M$26.52M
    Gross Profit$152.38M$131.96M$117.89M$111.15M$97.29M$85.78M$76.13M$56.45M$62.80M$66.30M$48.47M$56.87M
    Operating Expenses$98.15M$104.77M$88.63M$91.38M$73.27M$65.62M$62.85M$75.75M$72.46M$66.41M$65.02M$56.79M
    R&D$32.79M$40.90M$27.48M$34.61M$24.17M$18.75M$19.32M$35.22M$26.06M$24.02M$26.33M$20.05M
    SG&A$65.36M$63.87M$61.15M$56.77M$49.10M$46.86M$43.53M$40.53M$46.40M$42.40M$38.68M$36.74M
    Operating Income$54.24M$27.19M$29.27M$19.77M$24.02M$20.16M$13.27M$-19,299,000$-9,658,000$-117,000$-16,542,000$81,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$59.06M$31.14M$32.68M$23.27M$27.16M$22.88M$15.56M$-16,979,000$-7,201,000$2.30M$-14,276,000$2.45M
    Income Tax Expense$11.71M$5.71M$10.09M$9.07M$8.72M$5.04M$7.03M$-8,091,000$5.49M$6.21M$3.43M$-22,787,000
    Net Income$47.34M$25.43M$22.59M$14.20M$18.43M$17.83M$8.54M$-8,888,000$-12,693,000$-3,908,000$-17,704,000$25.24M
    EBITDA$59.20M$31.71M$34.45M$22.81M$28.14M$22.39M$16.16M$-15,760,000$-7,289,000$2.55M$-13,513,000$2.69M
    EBIT$59.06M$31.14M$32.68M$23.27M$27.16M$22.88M$15.56M$-16,979,000$-7,201,000$2.30M$-14,276,000$2.45M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KNSA

    Government Contracts

    Gov Obligations (TTM)
    $328283
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    6
    New Awards (TTM)
    5
    Avg Remaining Term
    4.3 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0076Department of Veterans AffairsDepartment of Veterans Affairs$220229Dec 15, 2025
    36C24526N0595Department of Veterans AffairsDepartment of Veterans Affairs$34023May 21, 2026
    36C24526N0418Department of Veterans AffairsDepartment of Veterans Affairs$34023Mar 18, 2026
    36C24526N0294Department of Veterans AffairsDepartment of Veterans Affairs$34023Jan 31, 2026
    36C24526N0196Department of Veterans AffairsDepartment of Veterans Affairs$32187Dec 22, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Kiniksa's Michael R. Megna Executes Stock Options and Sells Shares Up to $98.48 on October 30, 2026

    Michael R. Megna, Chief Accounting Officer at Kiniksa Pharmaceuticals International, plc, exercised stock options for 19,895 shares and subsequently sold 36,260 Class A Ordinary Shares on October 30...

    Kalkine Media•11/4/26•Neutral

    A CEO exercises options at $8.83 as his trust sells Kiniksa (KNSA) shares.

    Kiniksa Pharmaceuticals International, plc (KNSA) Chairman and CEO Sanj K. Patel exercised options on multiple dates in late October and early November 2026, acquiring shares at $8.83 and $17.92. Concurrently...

    Stock Titan•11/3/26•Bearish

    Under a preset trading plan, Kiniksa (KNSA) officer sells 36,260 shares.

    Michael R. Megna, Chief Accounting Officer at Kiniksa Pharmaceuticals International, plc (KNSA), sold 36,260 Class A ordinary shares on October 30, 2026...

    Stock Titan•11/3/26•Somewhat-Bearish

    Under a trading plan, Kiniksa (KNSA) medical chief exercises options and sells 96,000 shares.

    John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc (KNSA), exercised options and sold 96,000 Class A ordinary shares between October 30 and November 2...

    Stock Titan•11/3/26•Neutral

    An officer proposes selling Kiniksa (NASDAQ: KNSA) shares acquired through a cashless option exercise.

    Kiniksa Pharmaceuticals International, plc (KNSA) officer Mark Ragosa has proposed selling 36,783 Class A ordinary shares, valued at approximately $3.39 million, through Charles Schwab & Co....

    Stock Titan•11/2/26•Somewhat-Bearish

    KNSA Valuation and Fair Value

    P/E
    72.2x
    Forward P/E
    58.8x
    EV/EBITDA
    49.0x
    P/FCF
    37.2x
    P/B
    10.3x
    See GNG's fair value

    KNSA Profitability: Margins, ROIC and FCF

    Gross margin
    54.3%
    Operating margin
    19.0%
    Net margin
    11.6%
    ROE
    17.6%
    FCF margin
    20.8%
    FCF yield
    2.7%

    KNSA Competitors

    CompanyTicker
    Axsome Therapeutics IncAXSM
    Merus BVMRUS
    Praxis Precision Medicines IncPRAX
    Amneal Pharmaceuticals, Inc. Class A Common StockAMRX
    Caris Life Sciences, Inc. Common StockCAI
    Ionis Pharmaceuticals IncIONS
    Abivax SA American Depositary SharesABVX
    Lantheus Holdings IncLNTH

    Sector: Healthcare

    KNSA Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    1
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    KNSA Bull Case vs Bear Case

    Bull case

    • KNSA converts 20.8% of revenue into free cash flow.
    • KNSA grew quarterly revenue 58.1% year over year.
    • 100.0% of KNSA's analyst ratings are Buy or Strong Buy.

    Bear case

    • KNSA trades at 72.2x trailing earnings.
    • KNSA beat EPS estimates in 25.0% of its last 8 reported quarters.

    KNSA Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -90.5%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $1.15

    KNSA Earnings Date

    KNSA reports Feb 22, 2027. The date is estimated.

    KNSA Earnings Call

    The latest KNSA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    KNSA ETF Holders

    GNG tracks 4 ETFs that hold KNSA. The largest weights:

    1. Vanguard Morningstar Small-Cap Growth ETF (VBK), 0.09% of the fund
    2. Vanguard Health Care Index Fund ETF Shares (VHT), 0.04% of the fund
    3. Dimensional U.S. Core Equity 2 ETF (DFAC), 0.01% of the fund
    4. Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
    Open the ETF Stock Exposure tool for KNSA

    See insider activity

    Frequently Asked Questions About KNSA

    When does KNSA report earnings?

    Kiniksa Pharmaceuticals Ltd (KNSA) is expected to report earnings on Feb 22, 2027.

    Does KNSA pay dividends?

    Kiniksa Pharmaceuticals Ltd (KNSA) does not currently pay a regular dividend.

    What is KNSA's P/E ratio?

    Kiniksa Pharmaceuticals Ltd has a price-to-earnings (P/E) ratio of 72.20.

    What is KNSA's market cap?

    Kiniksa Pharmaceuticals Ltd (KNSA) has a market capitalization of $6.94B with a current stock price of $93.86.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In